Poor-prognosis cancers account for a disproportionate share of global cancer mortality despite major advances in prevention, early detection, and therapy for other malignancies.Launched in 2023, the G7 Cancer Initiative represents an unprecedented effort to address this challenge through coordinated scientific, clinical, and policy action.This report summarizes the outcomes of the G7 Cancer Conference held in Paris in June 2025, which focused on shifting poor-prognosis cancers from a paradigm of resignation to one of collective transformation.Discussions emphasized four interdependent pillars: precision medicine supported by multi-omic profiling and artificial intelligence; early detection and minimal residual disease monitoring using liquid biopsy and advanced imaging; innovative and adaptive clinical trial designs; and emerging therapeutic platforms, including nanomedicine, epigenetic therapies, and immune modulation.The meeting highlighted that scientific innovation alone is insufficient without harmonized infrastructures, equitable access, and international cooperation.Together, these elements form a new model of global cancer governance aimed at translating biological insight into meaningful survival gains for patients with historically lethal cancers.
Iovanna et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: